Trial · NCT04605926
A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19
NCT04605926, Phase 3, Withdrawn, Biocon Limited
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19. Trials, record NCT04605926. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04605926
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19
- NCT number
- NCT04605926
- Status
- Withdrawn
- Phases
- Phase 3
- Enrollment
- 0 participants, actual
- Lead sponsor
- Biocon Limited
- Conditions
- Coronavirus
- Interventions
- EQ001, EQ001 Placebo
- First posted
- 2020-10-28
- Last updated
- 2026-05-12
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of subjects who have recovered at Day 28. | Day 28 | Proportion of subjects who have recovered at Day 28. |
| Secondary | Proportion of subjects deceased or requiring mechanical ventilation at Day 28. | Day 28 | Proportion of subjects deceased or requiring mechanical ventilation at Day 28. |
| Secondary | Proportion of subjects deceased at Day 28. | Day 28 | Proportion of subjects deceased at Day 28. |
| Other | Incidence of treatment-emergent adverse events (TEAEs). | Day 90 | Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) |
| Other | Time to maximum itolizumab serum concentration, Tmax | Day 28 | Time to maximum itolizumab serum concentration, Tmax |
| Other | Maximum itolizumab serum drug concentration, Cmax | Day 28 | Maximum itolizumab serum drug concentration, Cmax |
| Other | Total itolizumab exposure across time, AUC (from zero to last) | Day 28 | Total itolizumab exposure across time, AUC (from zero to last) |
| Other | Inflammatory biomarkers | Day 28 | Including but not limited to IL-1, IL-6, IL-17, TNF-α. |
| Other | Pharmacodynamic markers | Day 28 | sCD6, sALCAM |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04605926
GET https://conductscience.org/api/trials/v1/NCT04605926/registered